Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Matthew Andrews is an analyst at Jefferies. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 03/30/2025
Buy Now | Get Alert | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
11/01/2023 | TGTX | Buy Now | TG Therapeutics | $39.88 | — | Matthew Andrews77% | — | Maintains | Buy | Get Alert |
02/06/2019 | CARA | Buy Now | Cara Therapeutics | $5.57 | 294.97% | Matthew Andrews77% | → $264 | Assumes | → Buy | Get Alert |
11/08/2018 | ALNA | Buy Now | Allena Pharmaceuticals | — | — | Matthew Andrews77% | → $22 | Assumes | → Buy | Get Alert |
09/13/2018 | CARA | Buy Now | Cara Therapeutics | $5.57 | 438.6% | Matthew Andrews77% | → $360 | Initiates | → Buy | Get Alert |
11/27/2017 | ALNA | Buy Now | Allena Pharmaceuticals | — | — | Matthew Andrews77% | → $22 | Initiates | → Buy | Get Alert |
09/12/2017 | CTIC | Buy Now | CTI BioPharma | — | — | Matthew Andrews77% | → $7.5 | Initiates | → Buy | Get Alert |
04/25/2017 | TGTX | Buy Now | TG Therapeutics | $39.88 | -42.33% | Matthew Andrews77% | → $23 | Initiates | → Buy | Get Alert |
03/21/2017 | GNMX | Buy Now | Aevi Genomic Medicine | — | — | Matthew Andrews77% | $10 → $2.5 | Downgrade | Buy → Hold | Get Alert |